Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan 430079, P.R.China.
J BUON. 2020 Mar-Apr;25(2):811-820.
This study aimed to explore the effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in bone metastasis of lung cancer.
82 patients with bone metastases of lung cancer who underwent targeted therapy combined with radiotherapy in Hubei Cancer Hospital were regarded as the experimental group, and another 64 patients with bone metastases of lung cancer who underwent conventional radiotherapy were regarded as the control group. Serum VEGF and COX-2 levels were measured by enzyme-linked immunosorbent assay (ELISA) before and after the treatment. The efficacy and adverse reactions of both groups were compared.
The levels of COX-2 and VEGF in serum of both groups were significantly lower than those before treatment (p<0.05). The effective rate and local tumor efficiency of the experimental group were significantly higher than those of the control group (p<0.05). The diarrhea and asthenia and vomiting events in the experimental group were significantly lower than those in the control group (p<0.05). No significant differences were found between the two groups in other adverse reactions (p>0.05). A significant positive correlation was found between COX-2 and VEGF in serum in the two groups before and after treatment; the survival rate of COX-2 and VEGF high expression group was significantly lower than in the low expression group (p<0.05); ECOG score, pathological type, COX-2 and VEGF level were independent risk factors of death in the experimental group.
Targeted therapy combined with radiotherapy has a strong inhibitory effect on the expression of COX-2 and VEGF in bone metastasis of lung cancer. There was a significant positive correlation between the expression of COX-2 and VEGF, and the use of targeted therapy combined with radiotherapy can significantly improve the efficacy and quality of life and to prolong survival.
本研究旨在探讨分子靶向治疗联合放疗对肺癌骨转移中环氧合酶-2（COX-2）和血管内皮生长因子（VEGF）表达及预后价值的影响。
选取湖北省肿瘤医院收治的行靶向治疗联合放疗的 82 例肺癌骨转移患者作为实验组，另选取同期行常规放疗的 64 例肺癌骨转移患者作为对照组。采用酶联免疫吸附试验（ELISA）检测两组患者治疗前后血清 VEGF 和 COX-2 水平，比较两组患者的疗效及不良反应。
两组患者治疗后血清 COX-2 和 VEGF 水平均显著低于治疗前（p<0.05）；实验组患者的有效率和局部肿瘤有效率均显著高于对照组（p<0.05）；实验组患者腹泻、乏力和呕吐发生率均显著低于对照组（p<0.05）；两组患者其他不良反应发生率比较差异无统计学意义（p>0.05）。两组患者治疗前后血清 COX-2 和 VEGF 呈显著正相关；COX-2 和 VEGF 高表达组患者的生存率均显著低于低表达组（p<0.05）；ECOG 评分、病理类型、COX-2 和 VEGF 水平是实验组患者死亡的独立危险因素。
靶向治疗联合放疗对肺癌骨转移中 COX-2 和 VEGF 的表达具有较强的抑制作用，COX-2 和 VEGF 的表达呈显著正相关，且采用靶向治疗联合放疗可显著提高疗效和生活质量，延长生存。
